Ghofrani Hossein A, Osterloh Ian H, Grimminger Friedrich
Medical Clinic II/V, Department of Internal Medicine, University Hospital Giessen and Marburg, GmbH, Klinikstrasse 36, 35392 Giessen, Germany.
Nat Rev Drug Discov. 2006 Aug;5(8):689-702. doi: 10.1038/nrd2030.
In less than 20 years, the first selective type 5 phosphodiesterase inhibitor, sildenafil, has evolved from a potential anti-angina drug to an on-demand oral treatment for erectile dysfunction (Viagra), and more recently to a new orally active treatment for pulmonary hypertension (Revatio). Here we describe the key milestones in the development of sildenafil for these diverse medical conditions, discuss the advances in science and clinical medicine that have accompanied this journey and consider possible future indications for this versatile drug.
在不到20年的时间里，首个选择性5型磷酸二酯酶抑制剂西地那非，已从一种潜在的抗心绞痛药物演变为按需口服治疗勃起功能障碍的药物（伟哥），最近又成为一种治疗肺动脉高压的新型口服活性药物（瑞伐托）。在此，我们描述西地那非针对这些不同医疗状况的研发关键里程碑，讨论伴随这一历程的科学与临床医学进展，并思考这种多功能药物未来可能的适应症。
